Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus.

Literature DB >> 9527790

TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus.

F M Uckun¹, L M Chelstrom, L Tuel-Ahlgren, I Dibirdik, J D Irvin, M C Langlie, D E Myers.

Abstract

We have evaluated the clinical potential of TXU (anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate (TXU-PAP) as a new biotherapeutic anti-human immunodeficiency virus (anti-HIV) agent by evaluating its anti-HIV type 1 (anti-HIV-1) activity in vitro, as well as in a surrogate human peripheral blood lymphocyte-severe combined immunodeficient (Hu-PBL-SCID) mouse model of human AIDS. The present report documents in a side-by-side comparison the superior in vitro anti-HIV-1 activity of TXU-PAP compared to the activities of zidovudine, 2',3'-didehydro-2',3'-dideoxythymidine, unconjugated PAP, and B53-PAP, an anti-CD4-PAP immunoconjugate. Notably, TXU-PAP elicited potent anti-HIV activity in the Hu-PBL-SCID mouse model of human AIDS without any side effects and at doses that were very well tolerated by cynomolgus monkeys. Furthermore, plasma samples from TXU-PAP-treated cynomolgus monkeys showed potent anti-HIV-1 activity in vitro.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1998 PMID： 9527790 PMCID： PMC105418 DOI： 10.1128/AAC.42.2.383

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

21 in total

1. Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals.

Authors: J A Levy; J Shimabukuro
Journal: J Infect Dis Date: 1985-10 Impact factor: 5.226

2. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells.

Authors: C Y Ou; S Kwok; S W Mitchell; D H Mack; J J Sninsky; J W Krebs; P Feorino; D Warfield; G Schochetman
Journal: Science Date: 1988-01-15 Impact factor: 47.728

3. Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection.

Authors: J Goudsmit; J M Lange; D A Paul; G J Dawson
Journal: J Infect Dis Date: 1987-03 Impact factor: 5.226

Review 4. Pathogenesis of infection with human immunodeficiency virus.

Authors: D D Ho; R J Pomerantz; J C Kaplan
Journal: N Engl J Med Date: 1987-07-30 Impact factor: 91.245

Review 5. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors: A S Fauci
Journal: Science Date: 1988-02-05 Impact factor: 47.728

6. Inhibition of herpes simplex virus multiplication by the pokeweed antiviral protein.

Authors: G M Aron; J D Irvin
Journal: Antimicrob Agents Chemother Date: 1980-06 Impact factor: 5.191

Review 7. Pokeweed antiviral protein.

Authors: J D Irvin
Journal: Pharmacol Ther Date: 1983 Impact factor: 12.310

8. The inhibition of infection by cucumber mosaic virus and influenza virus by extracts from Phytolacca americana.

Authors: J A Tomlinson; V M Walker; T H Flewett; G R Barclay
Journal: J Gen Virol Date: 1974-02 Impact factor: 3.891

9. Human immunodeficiency virus type 1 detected in all seropositive symptomatic and asymptomatic individuals.

Authors: J B Jackson; S Y Kwok; J J Sninsky; J S Hopsicker; K J Sannerud; F S Rhame; K Henry; M Simpson; H H Balfour
Journal: J Clin Microbiol Date: 1990-01 Impact factor: 5.948

10. Inhibition of herpes simplex virus DNA synthesis by pokeweed antiviral protein.

Authors: G J Teltow; J D Irvin; G M Aron
Journal: Antimicrob Agents Chemother Date: 1983-03 Impact factor: 5.191

13 in total

1. In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice.

Authors: Fatih M Uckun; Sanjive Qazi; Sharon Pendergrass; Elizabeth Lisowski; Barbara Waurzyniak; Chun-Lin Chen; T K Venkatachalam
Journal: Antimicrob Agents Chemother Date: 2002-11 Impact factor: 5.191

2. Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations.

Authors: Fatih M Uckun; Sharon Pendergrass; T K Venkatachalam; Sanjive Qazi; Douglas Richman
Journal: Antimicrob Agents Chemother Date: 2002-11 Impact factor: 5.191

Review 3. Ribosome inactivating proteins from plants inhibiting viruses.

Authors: Inderdeep Kaur; R C Gupta; Munish Puri
Journal: Virol Sin Date: 2011-12-10 Impact factor: 4.327

4. Functional Analysis of a Type-I Ribosome Inactivating Protein Balsamin from Momordica balsamina with Anti-Microbial and DNase Activity.

Authors: Parminder Kaur Ajji; Ken Walder; Munish Puri
Journal: Plant Foods Hum Nutr Date: 2016-09 Impact factor: 3.921

5. Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity.

Authors: Fatih M Uckun; Francis Rajamohan; Sharon Pendergrass; Zahide Ozer; Barbara Waurzyniak; Chen Mao
Journal: Antimicrob Agents Chemother Date: 2003-03 Impact factor: 5.191

6. A switch-on mechanism to activate maize ribosome-inactivating protein for targeting HIV-infected cells.

Authors: Sue Ka-Yee Law; Rui-Rui Wang; Amanda Nga-Sze Mak; Kam-Bo Wong; Yong-Tang Zheng; Pang-Chui Shaw
Journal: Nucleic Acids Res Date: 2010-06-17 Impact factor: 16.971

7. Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase.

Authors: E A Sudbeck; C Mao; R Vig; T K Venkatachalam; L Tuel-Ahlgren; F M Uckun
Journal: Antimicrob Agents Chemother Date: 1998-12 Impact factor: 5.191